A Look At Sinopharm Group (SEHK:1099) Valuation After The Proposed 2025 Final Dividend Announcement

Simply Wall St.03-28

Sinopharm Group (SEHK:1099) has drawn investor attention after its board proposed a final dividend of CN¥0.69 per share for 2025, totaling about CN¥2.15b, subject to approval at the June 18 AGM. See ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622004078?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6031000-choice2-main-header/1585186857496","is_english":true,"pubTime":"2026-03-28 10:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622004078","market":"hk","top_or_hot":-1,"title":"A Look At Sinopharm Group (SEHK:1099) Valuation After The Proposed 2025 Final Dividend Announcement","media":"Simply Wall St.","content":"<div>\n<p>Sinopharm Group (SEHK:1099) has drawn investor attention after its board proposed a final dividend of CN¥0.69 per share for 2025, totaling about CN¥2.15b, subject to approval at the June 18 AGM. See ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/healthcare/hkg-1099/sinopharm-group-shares/news/a-look-at-sinopharm-group-sehk1099-valuation-after-the-propo\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Sinopharm Group (SEHK:1099) Valuation After The Proposed 2025 Final Dividend Announcement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Sinopharm Group (SEHK:1099) Valuation After The Proposed 2025 Final Dividend Announcement\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-28 10:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/healthcare/hkg-1099/sinopharm-group-shares/news/a-look-at-sinopharm-group-sehk1099-valuation-after-the-propo><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sinopharm Group (SEHK:1099) has drawn investor attention after its board proposed a final dividend of CN¥0.69 per share for 2025, totaling about CN¥2.15b, subject to approval at the June 18 AGM. See ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/healthcare/hkg-1099/sinopharm-group-shares/news/a-look-at-sinopharm-group-sehk1099-valuation-after-the-propo\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1500","symbol_name":"做空集合股","start_time":0,"source_url":"https://simplywall.st/stocks/hk/healthcare/hkg-1099/sinopharm-group-shares/news/a-look-at-sinopharm-group-sehk1099-valuation-after-the-propo","article_id":"2622004078","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6031000-choice2-main-header/1585186857496"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/healthcare/hkg-1099/sinopharm-group-shares/news/a-look-at-sinopharm-group-sehk1099-valuation-after-the-propo","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622004078","pubTimestamp":1774663704,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Sinopharm Group (SEHK:1099) has drawn investor attention after its board proposed a final dividend of CN¥0.69 per share for 2025, totaling about CN¥2.15b, subject to approval at the June 18 AGM.\nSee our latest analysis for Sinopharm Group.\nThe proposed dividend comes after a period where momentum has been mixed, with a 30 day share price return showing a decline of 7.38% and a one year total shareholder return of 15.09%. This suggests recent weakness against a stronger longer term outcome.\nIf...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1500":"做空集合股","LU0640798160.USD":"EASTSPRING INVESTMENTS GLOBAL EMERGING MARKET DYNAMIC \"A\" (USD) ACC","BK1515":"抗疫概念","01099":"国药控股","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","LU1115378108.SGD":"Eastspring Investments - Global Emerging Markets Dynamic AS SGD","BK1197":"保健护理产品经销商"},"translate_title":"国药集团（SEHK：1099）公布2025年末期股息后的估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01099":0.9,"DCF":1},"content_text":"Sinopharm Group (SEHK:1099) has drawn investor attention after its board proposed a final dividend of CN¥0.69 per share for 2025, totaling about CN¥2.15b, subject to approval at the June 18 AGM. See our latest analysis for Sinopharm Group. The proposed dividend comes after a period where momentum has been mixed, with a 30 day share price return showing a decline of 7.38% and a one year total shareholder return of 15.09%. This suggests recent weakness against a stronger longer term outcome. If this dividend announcement has you reassessing healthcare exposure, it could be a good moment to see what else is on the move through our screener of 124 healthcare AI stocks With the shares down 7.38% over the past month but showing a 15.09% total return over the past year, plus a proposed CN¥2.15b payout, is this a genuine value opportunity, or is the market already pricing in future growth? AdvertisementPrice-to-Earnings of 7.9x: Is it justified? At a last close of HK$20.34, Sinopharm Group is trading on a P/E of 7.9x, which screens as inexpensive compared to both its own fair ratio and sector peers. The P/E multiple compares the current share price to earnings per share and is a quick way to see how much investors are paying for each unit of profit. For Sinopharm Group, the current 7.9x level sits against earnings that are forecast to grow by about 8.08% per year, with revenue growth forecasts of 4.2% per year and a recent 0.8% yearly earnings growth rate over five years. Against that backdrop, the share price is described as trading at good value compared to peers and the wider Hong Kong Healthcare industry, and also screening as good value versus a fair P/E of 23x suggested by the SWS model. That fair ratio points to a level the market could move towards if sentiment and fundamentals stay aligned with those assumptions. However, the stock's current Return on Equity of 7.7% is described as low and net profit margins of 1.2% are slightly below last year. Compared to the Hong Kong Healthcare industry average P/E of 10.9x and a peer average of 49.9x, Sinopharm Group's 7.9x stands out as a much lower earnings multiple. The company is also described as trading at 69.1% below an estimated fair value, and screening as good value on several checks relative to both peers and the broader industry. Explore the SWS fair ratio for Sinopharm Group Result: Price-to-Earnings of 7.9x (UNDERVALUED) However, the recent 7.38% 30-day share price decline and a 3.55% total shareholder loss over three years highlight sentiment and execution risks that could challenge this valuation story. Find out about the key risks to this Sinopharm Group narrative. Another view from the SWS DCF model While the 7.9x P/E points to inexpensive earnings, the SWS DCF model presents an even starker picture. It suggests fair value closer to HK$65.79 versus the current HK$20.34, which screens as heavily undervalued. The key consideration is whether the cash flow assumptions behind that gap feel appropriate to you. Look into how the SWS DCF model arrives at its fair value. 1099 Discounted Cash Flow as at Mar 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Sinopharm Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 237 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps If this mix of potential risks and rewards feels finely balanced, now is a good time to look through the details yourself and form a clear view using the 3 key rewards and 1 important warning sign Ready to hunt for more investment ideas? If this opportunity feels interesting, do not stop here. The best portfolios often come from comparing several strong candidates side by side, not just one.  Spot potential mispricings early by scanning screener containing 592 high quality undiscovered gems that combine solid fundamentals with lower market attention. Build a core of stability by reviewing companies in the solid balance sheet and fundamentals stocks screener (381 results) to see which names might support long term resilience. Target cash returns more efficiently by checking out 470 dividend fortresses that focus on higher yields with supporting fundamentals.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622004078","isCrawlerRequest":true}